Mabworks
About:
Mabworks is a gene engineering mab company.
Website: http://www.mab-works.com/
Top Investors: CICC, Med-Fine Capital, Beijing E-town International Investment & Development, CITIC Securities, BOCOM International
Description:
Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.
Total Funding Amount:
$215M
Headquarters Location:
Beijing, Beijing, China
Founded Date:
2003-01-01
Founders:
Number of Employees:
251-500
Last Funding Date:
2020-04-16
IPO Status:
Public
Industries:
© 2025 bioDAO.ai